SIGA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 56.17% compared to SIGA Technologies's net margin of -49.65%. SIGA Technologies's return on equity of 32.37% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that NovaBay Pharmaceuticals has higher upside potential than SIGA Technologies, analysts believe NovaBay Pharmaceuticals is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 1.023, which suggesting that the stock is 2.284% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SIGA Technologies's net income of $45.8M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, SIGA Technologies's price-to-earnings ratio is 7.26x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 3.08x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 56.17% compared to SIGA Technologies's net margin of -2357.27%. SIGA Technologies's return on equity of 32.37% beat Palatin Technologies's return on equity of --.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than SIGA Technologies, analysts believe Palatin Technologies is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 1.023, which suggesting that the stock is 2.284% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Palatin Technologies quarterly revenues of $350K. SIGA Technologies's net income of $45.8M is higher than Palatin Technologies's net income of -$2.4M. Notably, SIGA Technologies's price-to-earnings ratio is 7.26x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 3.08x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of 56.17% compared to SIGA Technologies's net margin of -549.33%. SIGA Technologies's return on equity of 32.37% beat Voyager Therapeutics's return on equity of -21.07%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 407.89%. Given that Voyager Therapeutics has higher upside potential than SIGA Technologies, analysts believe Voyager Therapeutics is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 1.023, which suggesting that the stock is 2.284% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.773%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. SIGA Technologies's net income of $45.8M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, SIGA Technologies's price-to-earnings ratio is 7.26x while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 3.08x versus 2.29x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of 56.17% compared to SIGA Technologies's net margin of -296.76%. SIGA Technologies's return on equity of 32.37% beat Zevra Therapeutics's return on equity of -208.85%.

SIGA Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 213.41%. Given that Zevra Therapeutics has higher upside potential than SIGA Technologies, analysts believe Zevra Therapeutics is more attractive than SIGA Technologies.

SIGA Technologies has a beta of 1.023, which suggesting that the stock is 2.284% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.938, suggesting its more volatile than the S&P 500 by 93.751%.

SIGA Technologies has a quarterly dividend of $0.60 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SIGA Technologies pays 72.05% of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

SIGA Technologies quarterly revenues are $81.5M, which are larger than Zevra Therapeutics quarterly revenues of $12M. SIGA Technologies's net income of $45.8M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, SIGA Technologies's price-to-earnings ratio is 7.26x while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SIGA Technologies is 3.08x versus 13.51x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.